{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:03:57Z","timestamp":1790949837098,"version":"4.1.0"},"reference-count":28,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Systemic therapy, including immune checkpoint inhibitors, has improved survival in advanced hepatocellular carcinoma (HCC); however, its efficacy remains limited in patients with macroscopic vascular invasion (MVI), a subgroup with an extremely poor prognosis. Although combining immunotherapy with local treatments such as hepatic arterial infusion chemotherapy (HAIC) and radiation therapy (RT) is considered a promising approach, robust supportive evidence from routine clinical practice is lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to evaluate the safety and therapeutic effectiveness of a multidisciplinary treatment strategy involving RT after HAIC, followed by immunotherapy, in patients with MVI-positive HCC, using real-world clinical data from Japan.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This is a prospective, multicenter registry study conducted at 3 hospitals in Hiroshima Prefecture, Japan. Eligible patients will have unresectable MVI-positive HCC confirmed by dynamic computed tomography. The treatment protocol follows a standardized sequence: 1 session of HAIC (cisplatin), RT targeting the MVI site (25 Gy in 5 fractions), and subsequent systemic immunotherapy. The primary end point is safety, which will be evaluated using the Common Terminology Criteria for Adverse Events (version 5.0). The secondary end points include progression-free survival at 12 and 24 weeks, tumor response, median progression-free survival, overall survival, and objective response rate at 12 and 24 weeks, assessed according to the Response Evaluation Criteria in Solid Tumors criteria. Data will be collected prospectively and analyzed according to the intention-to-treat principle.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Patient enrollment began in March 2025, and data collection and analysis are ongoing as participants continue to be followed.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This prospective registry study will generate real-world evidence on the safety and effectiveness of a multidisciplinary strategy combining HAIC, RT, and immunotherapy in patients with MVI-positive HCC. Given that all components are covered under Japan\u2019s national health insurance, this approach could be readily implemented in clinical practice and may inform future treatment guidelines for MVI-positive HCC.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/82992","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:15:07Z","timestamp":1771416907000},"page":"e82992-e82992","source":"Crossref","is-referenced-by-count":1,"title":["Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-994X","authenticated-orcid":false,"given":"Yoshiko","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-2156","authenticated-orcid":false,"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8074-244X","authenticated-orcid":false,"given":"Yumi","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7762-4629","authenticated-orcid":false,"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6971-6050","authenticated-orcid":false,"given":"Michiyo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5526-3293","authenticated-orcid":false,"given":"Masashi","family":"Hieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9617-4843","authenticated-orcid":false,"given":"Masakazu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1629-6259","authenticated-orcid":false,"given":"Hideki","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2232-1207","authenticated-orcid":false,"given":"Ippei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5361-9004","authenticated-orcid":false,"given":"Hideaki","family":"Kakizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-6560","authenticated-orcid":false,"given":"Nami","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-835X","authenticated-orcid":false,"given":"Keiji","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-1506","authenticated-orcid":false,"given":"Nobuki","family":"Imano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-3010","authenticated-orcid":false,"given":"Yuji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4165-2179","authenticated-orcid":false,"given":"Saki","family":"Sueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1887-1096","authenticated-orcid":false,"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-8287","authenticated-orcid":false,"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-0743","authenticated-orcid":false,"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"4","key":"R1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","journal-title":"N Engl J Med"},{"issue":"10126","key":"R2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","journal-title":"Lancet"},{"issue":"20","key":"R3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","journal-title":"N Engl J Med"},{"issue":"8","key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","journal-title":"NEJM Evid"},{"issue":"10492","key":"R5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","journal-title":"Lancet"},{"issue":"5","key":"R6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines)","volume":"53","author":"Hasegawa","journal-title":"Hepatol Res"},{"issue":"3","key":"R7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","journal-title":"J Hepatol"},{"issue":"4","key":"R8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","journal-title":"J Hepatol"},{"issue":"7","key":"R9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","journal-title":"JAMA Oncol"},{"issue":"6","key":"R10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"R11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1159\/000508724","article-title":"Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma","volume":"9","author":"Ueshima","journal-title":"Liver Cancer"},{"issue":"24","key":"R12","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study","volume":"37","author":"Wei","journal-title":"J Clin Oncol"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000513706","article-title":"Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein","volume":"10","author":"Kosaka","journal-title":"Liver Cancer"},{"issue":"2","key":"R14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.21037\/jgo-22-858","article-title":"Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan","volume":"14","author":"Wu","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"R15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00535-023-01976-x","article-title":"Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis","volume":"58","author":"Fu","journal-title":"J Gastroenterol"},{"issue":"2","key":"R16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.acra.2024.08.058","article-title":"Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib plus PD-1 inhibitors in hepatocellular carcinoma patients with tumor thrombosis in the inferior vena cava and\/or right atrium","volume":"32","author":"Lou","journal-title":"Acad Radiol"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-025-01306-9","article-title":"Comprehensive review of transarterial chemoembolization plus systemic therapy in advanced hepatocellular carcinoma","volume":"56","author":"Akyildiz","journal-title":"J Gastrointest Cancer"},{"issue":"7","key":"R18","doi-asserted-by":"publisher","first-page":"e922","DOI":"10.1093\/oncolo\/oyae048","article-title":"Concurrent atezolizumab plus bevacizumab and high-dose external beam radiotherapy for highly advanced hepatocellular carcinoma","volume":"29","author":"Su","journal-title":"Oncologist"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2017.11.027","article-title":"Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy","volume":"129","author":"Kim","journal-title":"Radiother Oncol"},{"issue":"5","key":"R20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051058","article-title":"Immunotherapy and radiation therapy combinatorial approaches in hepatocellular carcinoma","volume":"16","author":"Tojjari","journal-title":"Cancers (Basel)"},{"issue":"6","key":"R21","doi-asserted-by":"publisher","DOI":"10.1097\/MD9.0000000000000325","article-title":"Multidisciplinary treatment for patients with advanced hepatocellular carcinoma complicated by Vp4 portal vein tumor thrombosis: combination of atezolizumab and bevacizumab after hepatic arterial infusion chemotherapy and radiotherapy: a case series","volume":"5","author":"Yamaoka","journal-title":"Medicine (Abingdon)"},{"issue":"1","key":"R22","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02359-x","article-title":"Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study","volume":"22","author":"Naruto","journal-title":"BMC Gastroenterol"},{"issue":"15","key":"R23","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","journal-title":"J Clin Oncol"},{"issue":"5","key":"R24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","journal-title":"Ann Oncol"},{"issue":"36","key":"R25","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","journal-title":"J Clin Oncol"},{"key":"R26","unstructured":"Management of immunotherapy-related toxicities (version 1). National Comprehensive Cancer Network. 2025. URL: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1486 [Accessed 18-08-2025]"},{"issue":"12","key":"R27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","journal-title":"Ann Oncol"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1097\/ot9.0000000000000085","article-title":"Liver resection for hepatocellular carcinoma with vascular invasion: current insights and future perspectives","author":"Yuan","journal-title":"Oncol Transl Med"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e82992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:17:04Z","timestamp":1782843424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e82992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2196\/82992","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"v15i4e82992"}}